Ross Moat - May 1, 2025 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Role
CHIEF COMMERCIAL OFFICER
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Stock symbol
KNSA
Transactions as of
May 1, 2025
Transactions value $
-$103,649
Form type
4
Date filed
5/5/2025, 04:54 PM
Previous filing
May 1, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Moat Ross CHIEF COMMERCIAL OFFICER 23 OLD BOND STREET, THIRD FLOOR, LONDON, UNITED KINGDOM /s/ Madelyn Zeylikman, Attorney-in-Fact 2025-05-05 0001857177

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Ordinary Share Options Exercise $68.4K +3.85K +40.89% $17.76 13.3K May 2, 2025 Direct F1
transaction KNSA Class A Ordinary Share Sale -$108K -3.85K -29.02% $28.00 9.42K May 2, 2025 Direct F1, F2
transaction KNSA Class A Ordinary Share Options Exercise $111K +6.27K +66.62% $17.76 15.7K May 5, 2025 Direct F1
transaction KNSA Class A Ordinary Share Sale -$176K -6.27K -39.98% $28.00 9.42K May 5, 2025 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Performance Share Unit Award $0 +4.98K $0.00 4.98K May 1, 2025 Class A Ordinary Share 4.98K Direct F4, F5, F6
transaction KNSA Performance Share Unit Award $0 +5.23K $0.00 5.23K May 1, 2025 Class A Ordinary Share 5.23K Direct F4, F5, F7
transaction KNSA Performance Share Option Award $0 +8.04K $0.00 8.04K May 1, 2025 Class A Ordinary Share 8.04K $27.74 Direct F5, F8
transaction KNSA Performance Share Option Award $0 +8.3K $0.00 8.3K May 1, 2025 Class A Ordinary Share 8.3K $27.74 Direct F5, F9
transaction KNSA Share Option Options Exercise $0 -3.85K -10.26% $0.00 33.7K May 2, 2025 Class A Ordinary Share 3.85K $17.76 Direct F1, F10
transaction KNSA Share Option Options Exercise $0 -6.27K -18.63% $0.00 27.4K May 5, 2025 Class A Ordinary Share 6.27K $17.76 Direct F1, F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024.
F2 This transaction was executed in multiple trades through a broker-dealer at prices ranging between $28.00 and $28.03. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F3 This transaction was executed in multiple trades through a broker-dealer at prices ranging between $28.00 and $28.04. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F4 Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee.
F5 The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement.
F6 The PSUs shall vest, if at all, upon the submission to the U.S. Food and Drug Administration (the "FDA") of a biologics license application for KPL-387 for the treatment of pericarditis, subject to the Participant's continued employment with the Company, with certain exceptions.
F7 The PSUs shall vest, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.
F8 The Performance Share Options shall vest and become exercisable, if at all, upon the submission to the FDA of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, with certain exceptions.
F9 The Performance Share Options shall vest and become exercisable, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.
F10 The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023.